Loading patent…
AssigneeCancer Research Technology Limited
InventorsRoy Bicknell, Steven Suchting, Lorna Mary Dyet Stewart
Estimating the term…
Provided are methods of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. Also provided are antibodies that have the amino acid sequences i) to iii), iv) to vi), or i) to vi): i) SEQ ID NO:9, ii) SEQ ID NO:10, iii) SEQ ID NO:11, iv) SEQ ID NO:13, v) SEQ ID NO:14, vi) SEQ ID NO:15. Further provided are methods of inhibiting angiogenesis in an individual in need thereof comprising administering the extracellular domain (residues 1-467) of MR, or a fragment thereof, that inhibits angiogenesis, to the individual. Methods of inhibiting endothelial cell migration and/or proliferation comprising administering the extracellular domain of MR, or a fragment thereof, that inhibits endothelial cell migration and/or proliferation are also provided.
A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region (residues 1-467, SEQ ID NO:
Use of an antibody that selectively binds to the extracellular region of MR in the preparation of a medicament for inhibiting angiogenesis.
An in vitro method of inhibiting angiogenesis comprising administering an antibody that selectively binds to the extracellular region of MR to tissue or cells in vitro.
An antibody that contains the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or preferably the amino acid sequences i) to vi):
An antibody that selectively binds the Ig region of MR (residues 46-209, SEQ ID NO:
A method of combating a disease or condition selected from tumours/cancer, psoriasis, atherosclerosis, menorrhagia, endometriosis, arthritis (both inflammatory and rheumatoid), macular degeneration, Paget's disease, retinopathy and its vascular complications (including proliferative and of prematurity, and diabetic retinopathy), benign vascular proliferations, fibroses, obesity and inflammation in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of MR to the individual.
Use of an antibody that selectively binds to the extracellular region of MR in the preparation of a medicament for combating a disease or condition selected from tumours/cancer, psoriasis, atherosclerosis, menorrhagia, endometriosis, arthritis (both inflammatory and rheumatoid), macular degeneration, Paget's disease, retinopathy and its vascular complications (including proliferative and of prematurity, and diabetic retinopathy), benign vascular proliferations, fibroses, obesity and inflammation.
The MR ectodomain (SEQ ID NO:
The MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, or a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits endothelial cell migration and/or proliferation, for use in medicine.
A pharmaceutical composition comprising the MR ectodomain, or a fragment thereof that inhibits endothelial cell migration and/or proliferation, or a polynucleotide encoding the MR ectodomain or fragment thereof, and a pharmaceutically acceptable carrier.
A method of combating a disease or condition involving unwanted, undesirable or inappropriate endothelial cell migration and/or proliferation in an individual, the method comprising administering the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, or a polynucleotide encoding the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, to the individual.
Use of the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, or a polynucleotide encoding the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, in the preparation of a medicament for combating a disease or condition involving unwanted, undesirable or inappropriate endothelial cell migration and/or proliferation.
An in vitro method of inhibiting endothelial cell migration and/or proliferation comprising administering the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, a polynucleotide encoding the MR ectodomain or a fragment thereof that inhibits endothelial cell migration and/or proliferation, to tissue or cells in vitro.
A vector comprising a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits endothelial cell migration and/or proliferation.
The MR ectodomain, or a fragment thereof that inhibits angiogenesis.
A method of inhibiting angiogenesis in an individual in need thereof comprising administering the MR ectodomain, or a fragment thereof that inhibits angiogenesis, to the individual.
A method of combating a disease or condition selected from tumours/cancer, psoriasis, atherosclerosis, menorrhagia, endometriosis, arthritis (both inflammatory and rheumatoid), macular degeneration, Paget's disease, retinopathy and its vascular complications (including proliferative and of prematurity, and diabetic retinopathy), benign vascular proliferations, fibroses, obesity and inflammation in an individual in need thereof comprising administering the MR ectodomain, or a fragment thereof that inhibits angiogenesis, to the individual.
The MR ectodomain, or a fragment thereof that inhibits angiogenesis, for use in medicine.
Use of the MR ectodomain, or a fragment thereof that inhibits angiogenesis, in the preparation of a medicament for inhibiting angiogenesis.
Use of the MR ectodomain, or a fragment thereof that inhibits angiogenesis, in the preparation of a medicament for combating a disease or condition selected from tumours/cancer, psoriasis, atherosclerosis, menorrhagia, endometriosis, arthritis (both inflammatory and rheumatoid), macular degeneration, Paget's disease, retinopathy and its vascular complications (including proliferative and of prematurity, and diabetic retinopathy), benign vascular proliferations, fibroses, obesity and inflammation.
An in vitro method of inhibiting angiogenesis comprising administering the MR ectodomain, or a fragment thereof that inhibits angiogenesis, to tissue or cells in vitro.
A method of inhibiting angiogenesis in an individual in need thereof comprising administering a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits angiogenesis.
A polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits angiogenesis, for use in medicine.
Use of a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits angiogenesis, in the preparation of a medicament for inhibiting angiogenesis.
An in vitro method of inhibiting angiogenesis comprising administering a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits angiogenesis, to tissue or cells in vitro.
A vector comprising a polynucleotide encoding the MR ectodomain, or a fragment thereof that inhibits angiogenesis.
A pharmaceutical composition comprising the MR ectodomain, or a fragment thereof that inhibits angiogenesis, or a polynucleotide encoding the MR ectodomain or fragment thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.